CRPC

AcronymDefinition
CRPCChartered Retirement Planning Counselor (College for Financial Planning)
CRPCCastration-Resistant Prostate Cancer
CRPCCenter for Research on Parallel Computation (Rice University)
CRPCCoral Ridge Presbyterian Church (Fort Lauderdale, Florida)
CrPCCriminal Procedures Code
CRPCCanadian Police Research Centre
CRPCCentral Resume Processing Center (US Army)
CRPCConsumer Rights Protection Committee (Egypt)
CRPCCedar Rapids Photo Copy (Cedar Rapids, IA)
References in periodicals archive ?
They found that HSD17B4 expression levels were relatively the same in benign and local prostate cancer tissue, but significantly reduced in CRPC tissue, suggesting that HSD17B4 does play a role in preventing progression to CRPC.
He holds the CRPC designation, and previously served as the Chairman of the board for Junior Achievement of the Eastern Shore.
CRPC without mCRPC with minimal metastases or no symptoms Scondary hormonal Abiraterone theraphy Enzalutamide * Screen for metastases based on PSADT Docetaxel mCRPC with Post docetaxel symptoms Docetaxel Abiraterone Readium-223 Enzalutamide Cabazitaxel Radium-223 1.
Over the course of the forecast period, GlobalData anticipates it will receive label extensions in non-metastatic CRPC and hormone-sensitive prostate cancer, making it available to virtually all prostate cancer patients segments, with the exception of those with localized disease.
Bayer submitted a Marketing Authorization Application to the EMA for radium-223 in December 2012 for the treatment of CRPC patients with bone metastases.
We look forward to learning more about the clinical utility of galeterone as a potentially differentiated treatment option for CRPC patients.
AstraZeneca says it felt that it was prudent to take an early view of the study after a trial indicating zibotentan monotherapy did not show a significant improvement in the primary endpoint of overall survival in patients with metastatic CRPC.
In September 2010, the Enthuse study 14 with zibotentan as CRPC monotherapy did not show a significant improvement in the primary endpoint, namely overall survival.
This submission is based on Phase 3 data from the pivotal ARN-509-003 (SPARTAN) clinical trial, which assessed the safety and efficacy of apalutamide versus placebo, in men with non-metastatic CRPC who have a rapidly rising prostate specific antigen (PSA) despite receiving continuous androgen deprivation therapy (ADT).
Bone metastases will occur in 90% of men with CRPC and can produce significant morbidity, including pain, pathologic fractures, spinal cord compression and bone marrow failure.
M2 PHARMA-December 26, 2017-Janssen NDA for Apalutamide as Treatment for Non-Metastatic CRPC Garners Priority Review from US FDA
This NDA submission for apalutamide was based on the company's Phase 3 data from the pivotal ARN-509-003 (SPARTAN) clinical trial, which assessed the safety and efficacy of apalutamide versus placebo in men with non-metastatic CRPC who have a rapidly rising prostate specific antigen (PSA) despite receiving continuous androgen deprivation therapy (ADT).